IncobotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation
What is the purpose of this trial?
The scientific aim this study is to investigate the efficacy of incobotulinumtoxinA (Xeomin) in the treatment of post-surgical/post radiation cancer pain. Botulinum type A toxins are shown to have a potent analgesic effect. Our hypothesis is that injection of incobotulinumtoxinA into the area of local pain at or around the area of post-surgical/post radiation scar relieves the focal cancer pain.
- 18 Years - 80 Years
- Merz Pharmaceuticals
- Last Updated:
- Study HIC#: